We use cookies to provide you with a better experience. By continuing to browse the site you are agreeing to our use of cookies in accordance with our Cookie Policy.
Accept
Home » Actavis Buys Alpharma's Generics Business for $810 Million
Actavis Buys Alpharma's Generics Business for $810 Million
November 1, 2005
Iceland-based drugmaker Actavis has taken another major step to expand its presence in the generics market, announcing that it plans to purchase Alpharma's U.S. and international generics businesses for roughly $810 million.